HADHA inhibitors belong to a specific chemical class that pertains to the realm of enzymology and metabolic pathways. These inhibitors are designed to interact with and modulate the activity of the enzyme known as Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha, abbreviated as HADHA. This enzyme plays a crucial role in the beta-oxidation of fatty acids, a fundamental process that takes place within the mitochondria of cells. The beta-oxidation of fatty acids is a tightly regulated process responsible for breaking down long-chain fatty acids into acetyl-CoA units, which are then utilized as energy sources by the cell. HADHA is a vital component of this process, catalyzing the dehydrogenation step that contributes to the overall energy production from fatty acid metabolism. Inhibitors targeting HADHA are designed to modulate its enzymatic activity, thereby potentially affecting the entire beta-oxidation pathway.
These inhibitors are synthesized using intricate chemical design and structure-activity relationship studies. By specifically interacting with the active site or binding domains of the HADHA enzyme, they can potentially alter its catalytic efficiency or binding affinity for substrate molecules, consequently impacting the breakdown of fatty acids and subsequent energy production. The development and study of HADHA inhibitors contribute to a deeper understanding of metabolic pathways, enzymatic mechanisms, and cellular bioenergetics. Researchers continue to investigate the precise molecular interactions between HADHA and its inhibitors, elucidating the potential implications for cellular metabolism. The exploration of this chemical class provides insights into the intricate biochemical processes that underlie energy generation within cells. As our knowledge of these inhibitors advances, it may offer opportunities for further scientific discovery and potential applications in various fields that require a comprehensive understanding of enzymology and metabolic regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1-(2,3,4-Trimethoxybenzyl)piperazine | 5011-34-7 | sc-297236 | 500 mg | $374.00 | ||
Originally developed for angina, trimetazidine has been investigated for its potential in inhibiting fatty acid oxidation by targeting HADHA. | ||||||
S-(+)-Etomoxir | 828934-40-3 | sc-220002 | 10 mg | $385.00 | ||
This compound inhibits the transport of long-chain fatty acids into mitochondria, effectively blocking their oxidation and impacting HADHA activity. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Used primarily for angina, perhexiline has been suggested to inhibit fatty acid oxidation, which could involve HADHA inhibition. | ||||||
Meldonium | 76144-81-5 | sc-207887 | 100 mg | $455.00 | 1 | |
Initially developed for heart conditions, mildronate has been reported to influence fatty acid metabolism, potentially through HADHA inhibition. | ||||||
L-Buthionine sulfoximine | 83730-53-4 | sc-200824 sc-200824A sc-200824B sc-200824C | 500 mg 1 g 5 g 10 g | $286.00 $442.00 $1532.00 $2975.00 | 26 | |
While primarily used as a glutathione synthesis inhibitor, L-BSO has been investigated for its impact on fatty acid metabolism, possibly involving HADHA inhibition. | ||||||
Streptozotocin (U-9889) | 18883-66-4 | sc-200719 sc-200719A | 1 g 5 g | $116.00 $530.00 | 152 | |
An antibiotic that can cause diabetes-like symptoms, streptozotocin has been associated with altered fatty acid metabolism, potentially by affecting HADHA. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $116.00 $230.00 | 12 | |
Initially identified as a male contraceptive, gossypol has been studied for its potential effects on mitochondrial function and fatty acid metabolism, potentially involving HADHA inhibition. | ||||||